Compare VLN & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLN | MDWD |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.8M | 181.1M |
| IPO Year | 2021 | 2013 |
| Metric | VLN | MDWD |
|---|---|---|
| Price | $1.67 | $13.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 822.0K | 101.8K |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.37 | $48.92 |
| Revenue Next Year | $16.99 | $35.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $12.52 |
| 52 Week High | $3.71 | $20.03 |
| Indicator | VLN | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 54.53 |
| Support Level | $1.40 | $12.52 |
| Resistance Level | $1.76 | $15.08 |
| Average True Range (ATR) | 0.07 | 0.48 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 14.55 | 78.39 |
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.